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a  b  s  t  r  a  c  t
In humans,  the ingestion  of the  combination  of  two or more  serotonin  (5-HT)-enhancing  drugs  but  also
of  a single  drug  in overdose  can  induce  serious  adverse  effects,  which  are  characteristics  of the  serotonin
syndrome  (SS).  In  mice,  acute  administration  of direct  and  indirect  5-HT  agonists  also  leads  to behavioral
and  autonomic  responses,  but in literature  different  responses  are  thought  to  be  essential.  In order  to
detect  common  behavioral  SS  responses  induced  by 5-HT-enhancing  drugs  with  different  mechanisms  of
action,  we  investigated  the  effects of  the  5-HT  precursor  5-hydroxy-l-tryptophan (5-HTP),  the  selective
serotonin  reuptake  inhibitor  (SSRI)  ﬂuoxetine  (FLX),  and  the  monoaminooxidase  (MAO)  inhibitor  tranyl-
cypromine  (TCP)  in male  NMRI  mice. The  drugs  were  administered  alone  or  in  combination  to investigate
additive  effects  or drug  potentiation.  Moreover,  we  compared  the 5-HT responses  to the  effects  induced
by the  dopamine,  noradrenaline,  and  cholinergic  agonists,  apomorphine  (APO),  atomoxetine  (ATO),  and
oxotremorine  (OXO).  Our results  show  that  the studied  5-HT-enhancing  drugs  induced  a  different  num-
ber of  concomitant  responses.  The  following  ﬁve  responses  consistently  and  dose-dependently  occurred
in NMRI  mice:  ﬂat body  posture,  hindlimb  abduction,  piloerection,  tremor,  and  decreased  rearings.  Like
in humans,  the  combination  of 5-HT-enhancing  drugs  leads  to a potentiation  of drug  effects.  With  the
exception  of  ﬂat  body  posture  the  responses  are  not  speciﬁc  for serotonergic  hyperactivity.  The ﬁndings
demonstrate  that  the  SS  in NMRI  mice  is a suitable  animal  model  for preclinical  research,  if it is  taken  into
account  that the spectrum  of  typical  responses  to  5-HT  enhancing  drugs  may  differ  depending  on drug
and  mouse  strain  and  that  some  responses  might  be  evoked  by  activation  of other  transmission  systems,
too.
© 2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: 5-HT, serotonin; 5-HTP, 5-hydroxy-l-tryptophan; APO, apo-
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xotremorine; SS, serotonin syndrome; SRI, serotonin reuptake inhibitor; SSRI,
elective serotonin reuptake inhibitor; TCP, tranylcypromine.
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1. Introduction
In humans, the serotonin syndrome (SS) is a potentially life
threatening disorder, induced by drugs raising the activity of the
serotonergic transmission system. An SS usually develops when
two drugs, which increase extracellular concentration of serotonin
(5-HT) or act as an agonist at 5-HT receptors, are ingested together.
However, it can also be induced by single drug use in overdose.
The symptomatology of the SS in man  includes a triad of motor
symptoms (e.g. myoclonus, tremor), autonomic responses (e.g.
hyperthermia, tachycardia), and altered mental state (e.g. agitation,
confusion; see [1,2]).
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In laboratory rodents, a syndrome of serotonergic hyperactiv-
ty can be evoked by the same drugs and drug combinations as in
an  [see 3,4]. A prerequisite for the translational application of the
urine SS as a preclinical screening test for unwanted drug effects
s to evaluate the predictive validity of the assessed responses and
heir speciﬁcity.
In mice, several responses of motor and autonomic systems have
een reported following the administration of 5-HT-enhancing
rugs or direct 5-HT agonists [see 3,4]. However, it is still a mat-
er of debate which responses are essential to determine the
S in mice [4–7]. Different authors consider different responses
s relevant and do not make use of the same spectrum of
esponses [e.g. 3,5,7,8,9–11]. In order to examine which signs
an be reliably provoked in a typical outbred mouse strain, we
ystematically investigated the effects of three 5-HT-enhancing
rugs with different mechanisms of action, i.e. the 5-HT precur-
or 5-hydroxtryptophan (5-HTP), the selective serotonin reuptake
nhibitor (SSRI) ﬂuoxetine (FLX), and the unspeciﬁc monoamine
xidase (MAO) inhibitor tranylcypromine (TCP), given alone and
n combination, in NMRI mice. The spectrum of the examined
ehavioral signs included fourteen responses that were fre-
uently reported in literature and can concomitantly be assessed
3,5,7,12].
The second aim of this study was to characterize the interaction
f 5-HT-enhancing drugs, i.e. to clarify if the effect of two 5-HT-
nhancing drugs concurrently administered is an additive one or
 drug potentiation effect. It is known from clinical studies that
ombined ingestion of two 5-HT-enhancing drugs with different
echanisms of action in therapeutic doses are more likely to elicit
n 5-HT toxidrome, suggesting a potentiation of unwanted drug
ffects [13,14]. In animal studies the “5-HTP potentiated behavioral
yndrome” [15] and the behavioral syndrome after “tryptophan
oading” [16] are examples for presumed potentiation effects in rats
nd mice. However, in these studies, 5-HTP or tryptophan were
iven in sub-effective doses. In our study combinations of 5-HT-
nhancing drugs in mild effective doses were used enabling us to
nalyze drug interactions.
In laboratory rodents, dopamine and noradrenaline agonists as
ell as parasympathomimetics also induce motor and autonomic
ffects, which are known to resemble some of the SS responses.
he third aim of our study in NMRI mice was hence to clarify
hich distinct responses to 5-HT-enhancing drugs are speciﬁc
nd which coincide with responses to agonists at dopamine, nor-
drenaline, and acetylcholine receptors. Therefore, we studied the
ffects induced by the dopamine receptor agonist apomorphine
APO), the noradrenaline reuptake inhibitor atomoxetine (ATO),
nd the unspeciﬁc muscarinic receptor agonist oxotremorine
OXO).
. Materials and methods
.1. Animals
Male NMRI mice (HsdWin:NMRI) at an age of 10 weeks were
sed in all experiments. The mice (n = 12–14 per group) were
btained from Harlan–Winkelmann (Horst, Netherlands) and were
abituated in the animal facility for at least two weeks. The mice
ere pair-housed under standardized conditions (23 ± 2 ◦C room
emperature, 50 ± 5% humidity) with an artiﬁcial 12/12 h light/dark
ycle (lights on 06.00–18.00 h, illumination strength ca. 250 lx).
ood (Altromin 1326, Lage, Germany) and tap water were available
d libitum. Experiments were performed according to the guide-
ines of the German Animal Protection Law and were approved
y the Berlin State Authority (“Landesamt für Gesundheit und
oziales”). Research 277 (2015) 204–210 205
2.2. Drug treatment
Fluoxetine (FLX; European Directorate for the Qual-
ity of Medicines & HealthCare (EDQM)), tranylcypromine
(TCP; (±)-trans-2-phenylcyclopropan-1-amine hydrochloride;
Sigma–Aldrich), apomorphine (APO; (R)-5,6,6a,7-tetrahydro-6-
methyl-4H-dibenzo[de,g]quinolone-10,11-diol hydrochloride;
Tocris Bioscience), oxotremorine (OXO; 1-[4-(1-pyrrolidinyl)-
2-butynyl]-2-pyrrolidinone sesquifumarate; Sigma–Aldrich),
and atomoxetine (ATO; (R)-N-methyl--(2-methylphenoxy)-
benzenepropanamine hydrochloride; Tocris Bioscience) were
freshly dissolved in 0.9% saline. 5-hydroxy-l-tryptophan (5-HTP;
Sigma–Aldrich) was  freshly prepared as a suspension in 0.9%
saline with 1% Cremophor EL. All drugs and vehicle were injected
intraperitoneally (i.p.) at a volume of 10 ml/kg body weight.
2.2.1. Experiment 1
In order to investigate SS responses after single drug admin-
istration the following dose ranges were used based on previous
studies [7,10]: for 5-HTP 80, 160, and 320 mg/kg, for FLX 10, 20,
and 40 mg/kg, and for TCP 1, 2, and 4 mg/kg. For ethical reasons,
the doses of these drugs were below the lethal one. The maximal
doses we  have chosen for 5-HTP, FLX, and TCP were about 1/4–1/3
of the respective LD50 administered i.p. in mice [17–19]. Since no
signiﬁcant differences were observed, the vehicle groups for 5-HTP,
FLX and TCP (n = 5, 5, and 4, respectively) were pooled to one control
group.
2.2.2. Experiment 2
For the investigation of drug interactions we concomitantly
administered 5-HTP with FLX, FLX with TCP, and 5-HTP with TCP in
their minimal effective dose obtained by Experiment 1, i.e. 80 mg/kg
5-HTP, 10 mg/kg FLX, and 2 mg/kg TCP respectively. All drug com-
binations were administered as one injection.
2.2.3. Experiment 3
The doses of APO (4 mg/kg), OXO (0.5 mg/kg), and ATO (2 mg/kg)
were chosen according to Lau et al. [20] and Maehara et al. [21] and
to our own experience.
2.3. Behavioral test
The mice were transferred to the experimental room 12 h prior
to the beginning of the experiment. On the following day between
08.00 and 12.00 h, the experiments were carried out in a sound
attenuated chamber. For each 90 min  trial four mice were tested
at the same time. Immediately after drug or vehicle injection, each
mouse was placed in the center of a black painted Makrolon type II
cage (260 mm × 200 mm × 140 mm)  and its behavior was evaluated
by an observer blind to drug treatment. Between each trail, the
cages were cleaned with a solution of water and detergent.
The assessment method for the SS responses was adapted
from previous studies [7,9,10]. Beginning 5 min post-injection, the
occurrence of the following SS responses was assessed every 5 min
for 1 min  by instantaneous sampling and was rated as present (=1)
or absent (=0):
• Flat body posture (the greater ventral part of the body is in con-
tact with the cage ﬂoor and the animal moves similar to a reptile.
To our experience ﬂat body posture is often accompanied by
hindlimb abduction)• Head weaving (repetitive movement of the head from side to side,
like watching a tennis match)
• Hindlimb abduction (both hindlimbs are splaying out to the side.
Toes of the distal limb are also often splayed out.)
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Tremor (shivering encompassing the whole body at rest)
Straub tail (a rigid dorsiﬂexed tail in a sharper angle at the base
of the tail)
Backward walking (the animal continuously moves backwards
for some cm)
Hunched back (dorsal arching of the spine relative to a line
between the neck and the rump with distinctive ﬂexion of the
back muscles)
Piloerection (erected body hair, most prominent in the region of
the neck)
Head shakes (short and ﬁrm movement of the head in any direc-
tion comparable to the Pinna reﬂex reaction)
Forepaw treading (the animal is at rest and moves the forepaws
alternating and repetitively)
Head twitches (jerky movements of the head only toward the
neck).
Additionally, as a measure for vertical activity the number of
earings (i.e. both forepaws lifted off the cage ﬂoor) was counted
very 5 min  for 1 min. At the end of the experiment, the animals
ere removed from the cage and the occurrence of salivation, rated
s present (=1) or absent (=0), was determined by closely examin-
ng the muzzle of the mice for patches of damp fur. Moreover, the
umber of defecation boli in the experimental cage was  counted.
he occurrence of any other effect mentioned in literature, e.g.
yoclonic seizures [22], was also registered by the observer.
Horizontal motor activity was not determined because of the
estricted area of the observation cages. Drug effects on rectally
ecorded body temperature were not included in this study as it
ould have interfered with the behavioral observation.
.4. Statistical analysis
Since no signiﬁcant behavioral changes were detected in the last
0 min  (60–90 min), we only analyzed the data of the ﬁrst 60 min
0–60 min), resulting in 12 assessment points. The scores measured
y instantaneous sampling were summed up for each a mouse with
 possible maximum value of 12 for each response. The number of
earings was summed up over the 12 assessment points. For all
reatment groups the means ± SEM for each response were calcu-
ated, except for salivation. Sign of salivation were only observed
n the OXO group and appeared there in all animals. Hence, for
alivation descriptive statistics were used.
In order to detect dose response effects (Experiment 1) or treat-
ent effects (Experiments 2 and 3), the data were analyzed using
ne-way ANOVAs followed by post hoc Dunnett’s tests in compar-
son to vehicle.
In order to investigate the synergistic effect of the drug combi-
ations, we calculated the respective sums of the single drug effects
or each SS response and analyzed the data by Mann–Whitney-U-
ests. For all tests a probability value of 0.05 was considered to be
tatistically signiﬁcant. In Tables 1–3, only those SS responses are
hown where signiﬁcant differences were detected.
. Results
.1. Experiment 1
5-HTP. Out of all three drugs, 5-HTP induced the broadest
pectrum of SS responses. Post hoc analysis revealed that, in com-
arison to vehicle, the higher doses of 5-HTP (i.e. 160 mg/kg and
20 mg/kg) signiﬁcantly increased the occurrence of the following
even responses: ﬂat body posture, hindlimb abduction, piloerec-
ion, tremor, forepaw treading, head twitches, and hunched back
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Table  2
Effects of 5-HTP, FLX, and TCP in combination on SS responses in NMRI mice.
Response Treatment vehicle Drug combination p value Addition of sum scores/numbers of the single drugs
5-HTP + FLX FLX + TCP 5-HTP + TCP 5-HTP/FLX FLX/TCP 5-HTP/TCP
80  + 10 mg/kg 10 + 2 mg/kg 80 + 2 mg/kg 80/10 mg/kg 10/2 mg/kg 80/2 mg/kg
Sum scores of
Flat body posture 0.38 ± 0.38 9.54 ± 0.40* 3.15 ± 1.02 7.33 ± 1.08* <0.001 0.58 ± 0.19 0.77 ± 0.34 1.31 ± 0.40
Hindlimb abduction 1.31 ± 0.84 9.38 ± 0.60* 8.38 ± 0.99 11.83 ± 0.17 <0.001 2.67 ± 0.73 7.23 ± 1.22 8.92 ± 1.39
Piloerection 2.00 ± 0.91 11.62 ± 0.21* 11.00 ± 0.52 12.00 ± 0.00* <0.001 15.67 ± 1.73 13.08 ± 1.61 20.00 ± 1.26
Tremor  0.69 ± 0.69 4.54 ± 0.84* 3.85 ± 0.85* 8.42 ± 0.63* <0.001 1.83 ± 0.52 1.31 ± 0.56 2.54 ± 0.40
Forepaw treading 0.46 ± 0.46 4.38 ± 0.49* 0.23 ± 0.12 2.17 ± 0.67 <0.001 1.75 ± 0.99 0.92 ± 0.92 0.69 ± 0.33
Head  twitches 0.62 ± 0.62 4.38 ± 0.72 0.69 ± 0.26 6.92 ± 0.87 <0.001 5.83 ± 0.92 0.85 ± 0.85 5.00 ± 0.84
Hunched back 0.23 ± 0.23 0.69 ± 0.24 0.31 ± 0.13 4.17 ± 0.98* <0.001 2.83 ± 0.98 2.00 ± 1.01 1.00 ± 0.36
Rearing  [n] 65.23 ± 6.71 3.69 ± 1.10* 37.77 ± 7.71* 13.50 ± 2.45* <0.001 89.33 ± 8.53 106.85 ± 76.62 76.62 ± 7.88
Defecation boli [n] 12.23 ± 1.31 5.77 ± 0.99* 10.31 ± 1.37* 17.17 ± 1.94* <0.001 35.75 ± 2.29 25.38 ± 1.67 30.92 ± 1.83
D  by on
d d num

































Data are presented as means ± SEM. P values for treatment effects were calculated
rug  combinations were analyzed by Dunnett’s tests versus vehicle, indicated as bol
cores/numbers of single drugs. 5-HTP = 5-hydroxy-l-tryptophan; FLX = ﬂuoxetine;
umbers of rearings (Table 1). At the lowest dose (80 mg/kg), 5-HTP
ncreased the occurrence of piloerection and head twitches and also
he number of defecation boli, whereas the number of rearings was
igniﬁcantly decreased (Table 1).
FLX. In comparison to 5-HTP, less responses were evoked
y FLX treatment. Compared to vehicle, the administration of
0 mg/kg and 40 mg/kg FLX induced signiﬁcant increases only in
he following ﬁve SS responses, ﬂat body posture, hindlimb abduc-
ion (although only signiﬁcant when treated with 20 mg/kg FLX),
iloerection, tremor, and hunched back (Table 1). In addition,
igniﬁcant decreases were revealed for number of rearings and
efecation boli (Table 1). At the lowest dose (10 mg/kg), FLX only
nduced an increase in the occurrence of hunched back (Table 1).
TCP. Of the three drugs, TCP elicited the fewest number of SS
esponses. At the highest dose (4 mg/kg), TCP only induced sig-
iﬁcant increases in the occurrence of ﬂat body posture, hindlimb
bduction, piloerection, and tremor, and additionally it decreased
he number of rearings (Table 1). Treatment with 2 mg/kg TCP
igniﬁcantly enhanced the occurrence of hindlimb abduction
p < 0.001) and piloerection (p < 0.001), whereas 1 mg/kg TCP had
o signiﬁcant effects on the assessed responses (Table 1).
Comparing all three single drug treatments, the following ﬁve
esponses were consistently observed: ﬂat body posture, hindlimb
bduction, piloerection, tremor, and decreased rearings. Backward
alking, head shakes, head weaving, salivation, and Straub tail did
ot occur after treatment with 5-HTP, FLX and TCP in NMRI mice
n any of the used doses (data not shown).
.2. Experiment 2
The minimal effective dose of each drug was used for inves-
igating drug interaction, i.e. the doses, derived by Experiment 1,
hich induced at least one SS response. 5-HTP at 80 mg/kg evoked
our responses, 10 mg/kg FLX induced one and 2 mg/kg TCP two
esponses (see Table 1). All three drug combinations increased
able 3
ffects of ATO, APO, and OXO on the ﬁve common SS responses and the Straub tail respon
Response Treatment vehicle ATO 
2  mg/kg 
Sum scores of
Flat body posture 0.13 ± 0.13 0.15 ± 0.10 
Hindlimb abduction 0.13 ± 0.13 3.46 ± 0.56 
Piloerection 0.56 ± 0.24 10.23 ± 0.67 
Tremor 0.00 ± 0.00 1.23 ± 0.65 
Rearing [n] 55.31 ± 5.54 44.31 ± 6.82 
ata are presented as means ± SEM. P values for treatment effects were calculated by o
unnett’s tests versus vehicle indicated as bold numbers. ns = not signiﬁcant; ATO = atome-way ANOVAs for each drug combination and response. Treatment effects of the
bers. *p < 0.05 analyzed by Mann–Whitney-U-tests versus the addition of the sums
 tranylcypromine.
the number of SS responses and at least the ﬁve aforementioned
responses (i.e. ﬂat body posture, hindlimb abduction, piloerection,
tremor, and a decrease in rearings) were observed (see Table 2). 5-
HTP + FLX. The combination of 80 mg/kg 5-HTP and 10 mg/kg FLX
additionally induced an increase in forepaw treading and head
twitches and a decrease of defecation boli (Table 2).
FLX + TCP. The combination of 10 mg/kg FLX with 2 mg/kg TCP
induced no further SS responses than the ﬁve aforementioned SS
responses (see Table 2).
5-HTP + TCP. After administration of 5-HTP (80 mg/kg) and TCP
(2 mg/kg) the broadest spectrum of responses was  observed. In
addition to the ﬁve aforementioned SS responses forepaw treading,
head twitches, hunched back, and an increased number of defeca-
tion boli occurred (see Table 2).
Likewise to the single treatments, all three combinations had no
signiﬁcant effects on backward walking, head shakes and weaving,
salivation and Straub tail (data not shown).
In order to characterize the synergism of the drug combina-
tions, the effects were compared to the respective addition of sum
scores/numbers of the single drugs (see Table 2). Arithmetically,
the sum scores/numbers for seven SS responses of the 5-HTP + FLX
combination were signiﬁcantly higher than the respective sums of
the single drug effects. Also, sum scores/numbers of the 5-HTP + TCP
combination exceeded the sums of the single drug effects in case
of six SS responses. The over-additive effect of the FLX + TCP com-
binations was not as pronounced: only the sum scores/numbers of
three SS responses differed from the sums of the single drug effects
(see Table 2).
3.3. Experiment 3Following the treatment with the noradrenaline agonist ATO
only two  of the ﬁve common SS responses in NMRI mice, i.e.
hindlimb abduction and piloerection, were observed (Table 3).
The administration of the dopamine agonist APO also increased
se in NMRI mice.
APO OXO p value
4 mg/kg 0.5 mg/kg
0.07 ± 0.07 0.00 ± 0.00 ns
3.21 ± 0.62 11.38 ± 0.40 <0.001
7.86 ± 1.08 7.23 ± 0.86 <0.001
0.00 ± 0.00 10.00 ± 0.85 <0.001
19.29 ± 2.93 0.77 ± 0.61 <0.001
ne-way ANOVAs for each drug and response. Treatment effects were analyzed by
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indlimb abduction and piloerection. Additionally, APO decreased
he number of rearings (see Table 3). The most responses in
his experiment were induced by the acetylcholine agonist OXO.
he administration of OXO increased the occurrence of hindlimb
bduction, piloerection, and tremor, and decreased the number of
earings (Table 3). For the ﬁrst time salivation was observed, which
as displayed in all 13 animals treated with OXO. Moreover, the
dministration of APO and OXO induced in some animals the Straub
ail response (sum scores for APO: 1.43 ± 0.64, for OXO: 2.00 ± 0.62;
 = 0.002 vs vehicle: 0.00 ± 0.00).
Of the ﬁve common SS responses induced by 5-HT-enhancing
rugs in NMRI mice, ﬂat body posture was not evoked by ATO, APO,
r OXO. Also, backward walking, changes in defecation, forepaw
reading, hunched back, head twitches, head weaving and head
hakes were not observed (data not shown).
. Discussion
In literature, ﬂat body posture, hindlimb abduction, tremor,
ead weaving, backward walking, Straub tail, and hyperactivity are
he most frequently reported signs for describing the SS in mice [see
]. Head twitches and decrease in body temperature are also often
eferred to as signs of serotonergic hyperactivity [3]. In order to
rove, whether this spectrum of signs is reliably induced by dif-
erent 5-HT-enhancing drugs we investigated the effects of 5-HTP,
LX, and TPH on the behavioral SS responses in male NMRI mice.
he selected drugs increase the extracellular 5-HT concentration
y different mechanisms of action and have been frequently used
o evoke SS responses in rodents [7,10,23–25].
In our study, we observed in NMRI mice ﬁve common signs
hat were induced by all three 5-HT-enhancing drugs, i.e. ﬂat body
osture, hindlimb abduction, tremor, piloerection, and decrease
n rearing. Likewise to humans, where the symptoms of the SS
re thought to be a continuous spectrum from side-effects to tox-
city [26], the severity and number of responses increased with
scending dosage. Although, the spectrum of signs is conﬁrmed
y other murine SS studies [5,7–10,15,27], it only partially over-
aps with the most frequently reported responses. Most likely,
train differences contribute to the diverging spectrum of signs
s it was previously shown that the intensity of head weaving
nd hindlimb abduction induced by the 5-HT precursor tryptamine
an differ between mouse strains due to different tryptamine con-
entrations in the brain [28]. Also the pharmacodynamics of the
erotonergic drugs can inﬂuence the range of evoked behavioral SS
esponses. In this study, the used drugs increase extracellular 5-HT
oncentration and therefore activate all 5-HT receptors. Hence, it
s conceivable that distinct behavioral responses might occur more
ronounced if only speciﬁc 5-HT receptor subtypes are stimulated.
n the same mouse strain, for example, we observed a rigid tail
also known as Straub tail or spontaneous tail ﬂick response) when
he full 5-HT1A-receptor agonist 8-OH-DPAT (1.25 and 2.5 mg/kg)
as administered [8]. Although we used rather high doses [17–19],
his response did not occur after the administration of the three
-HT-enhancing drugs.
Moreover, our results revealed that 5-HTP and FLX unequally
voked additional signs to the ﬁve common responses. Most
esponses were observed after treatment with the higher doses
160 and 320 mg/kg) of 5-HTP (8 out of 14), whereas TCP (4 mg/kg)
nd FLX (20 mg/kg) induced 5 and 7 responses out of 14, respec-
ively. The fact that 5-HTP magniﬁes 5-HT synthesis could account
or the efﬁcacy of this drug. Brain microdialysis experiments in rats
emonstrated that extracellular 5-HT increased to about 300% fol-
owing already a relatively low dose (75 mg/kg) of 5-HTP [29]. A
urther increase of 5-HTP doses raised the 5-HT release, measured
y an in vivo voltammetry study, in a proportional manner [30]. Research 277 (2015) 204–210
The tremendous elevation of central 5-HT by 5-HTP was explained
by conversion of 5-HTP to 5-HT, not only in serotonergic but also
in dopaminergic neurons [30]. Hence, the broader spectrum of
responses induced by 5-HTP in comparison to TCP and FLX might
be related to a stronger stimulation of speciﬁc 5-HT receptor sub-
types. Head twitches, for example, are regarded to be mediated by
5-HT2A receptor activation [22,31–34], forepaw treading is induced
by stimulation of 5-HT1A receptors [11], and 5-HTP induced defe-
cation is a well-known effect elicited by peripheral action of 5-HT,
especially at 5-HT4 receptors [35]. Moreover, the hunched back
has been shown to be due to stimulation of 5-HT2C receptors [36].
Besides the explanation that 5-HTP leads to a higher 5-HT release
than FLX and TCP, it has to be taken into account, that both drugs
possess secondary pharmacological properties including actions at
other transmission systems. TCP is an unselective inhibitor of MAO
A and B, thus inhibiting also the degradation of dopamine and nor-
adrenaline. FLX is known to increase noradrenaline and dopamine
extracellular levels in brain [37]. These secondary pharmacological
properties might have interfered with some of the SS responses.
In our study backward walking, head waving, head shakes, and
salivation could not be evoked by all three 5-HT-enhancing drugs.
In accordance to our results, backward walking, head shaking and
salivation also failed to appear in other mice studies after treat-
ment with 5-HTP [10,27]. Surprisingly, we did not observe the
Straub tail response in all treatment groups, although this response
is reported in corresponding studies [7,10,27]. As we have stated
above, we  assume that strain differences and procedural variables
may account for the variations in study results.
In summary, ﬂat body posture, hindlimb abduction and tremor
together with piloerection and decreased rearings turned out to be
the common SS responses following 5-HT-enhancing drugs in NMRI
mice. When establishing the model of SS in the lab, 5-HTP may
serve as the most appropriate positive control. However, it has to be
considered that other 5-HT-enhancing drugs that are used in phar-
macological research may  induce a diverse spectrum of behavioral
SS responses as shown by FLX and TCP.
The second aim of our study was to investigate, whether the
interaction of 5-HT-enhancing drugs can be described as an over-
additive effect. In laboratory rodents, a potentiation effect by
combination of 5-HT-enhancing drugs has been assumed and it
has been termed as the “5-HTP potentiated behavioral syndrome”
[15,38] and the behavioral syndrome “after tryptophan loading”
[16]. Drug potentiation (or over-additive synergism) can be phar-
macologically deﬁned as the joint effect of two  drugs that is greater
than the algebraic sum of their individual effects [39,40]. In order to
characterize the interaction pharmacologically, we identiﬁed ﬁrst
the minimal effective doses of 5-HTP (80 mg/kg), FLX (10 mg/kg),
and TCP (2 mg/kg), i.e. the dose which evoked at least one of the
SS responses in our experiments. Our results revealed that all com-
binations of the three 5-HT-enhancing drugs led to an increased
number of SS responses compared to single drug administration.
We additionally observed that the sum scores for each response
obtained by the drug combinations exceed markedly the addition
of the sums scores of the single drug effects. The only exception
is piloerection that reached almost the maximum sum already fol-
lowing low drug doses, indicating a ceiling effect. Taken together,
our ﬁndings of the drug combination experiments argue for an
over-additive synergistic effect. This is supported by brain micro-
dialysis studies in rats, which have shown that the elevation of 5-HT
levels by concomitantly given drugs is enlarged when compared
to the administration of each single drug. FLX caused a 2–4-fold
increase in extracellular 5-HT concentration in the neostriatum and
hypothalamus. When 5-HTP, in a dose which alone had only a small
effect was  added to FLX, the 5-HT release was 10–16-fold increased
[41,42]. Also clinical studies suggest a potentiation effect, since the
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nhibitors together with SRI or 5-HT releaser even in therapeutic
oses [26,43]. Hence, the SS in NMRI mice induced by the drug
ombinations seems to mirror the increased risk by concomitant
ngestion of two serotonin agonists.
In order to characterize the speciﬁcity of the SS model and
o examine a further aspect of predictive validity, the ﬁve com-
on responses induced by the serotonergic drugs used in this
tudy were compared to the effects of rather high doses of ago-
ists at the dopamine receptor (APO), the acetylcholine receptor
OXO), and the noradrenaline receptor (ATO). Of the ﬁve common
esponses induced by the three 5-HT-enhancing drugs, hindlimb
bduction, piloerection, tremor, and decrease in rearing were vari-
bly demonstrated after the administration of APO, OXO, and ATO.
e observed marked differences between the types of tremor: 5-
T-induced tremor was  mild, whereas the OXO-induced tremor
as severe and vigorous. Tremor induced by ATO was similar to 5-
T-induced tremor but was displayed only temporary in few mice.
he only response which was solely induced by the three 5-HT-
nhancing drugs, but not by APO, OXO, and ATO, was  ﬂat body
osture. This observation is in line with the general assumption
hat ﬂat body posture is a 5-HT1A receptor mediated drug effect,
specially by postsynaptic 5-HT1A receptors [see 44]. Interestingly,
n some animals treated with OXO and APO the Straub tail response
as induced. The Straub tail has also been reported by others in APO
r nicotine treated mice [45,46]. Taken together, the comparison of
he effects of the four different neurotransmitter agonists suggests
hat similar responses can also be evoked by drugs primarily affect-
ng other transmission systems. Therefore, when a drug screening
est is performed, we suggest to perform corresponding receptor
ntagonist studies.
Summarizing, we identiﬁed a spectrum of SS responses in
MRI mice that reliably and robustly manifested following the
dministration of 5-HTP, FLX, and TCP: ﬂat body posture, hindlimb
bduction, piloerection, tremor, and decrease in rearing. Subse-
uently, we demonstrated that the combinations of 5-HTP, FLX,
nd TCP have a drug potentiation effect. Our results strengthen the
redictive validity of the murine SS, arguing for its application as a
ranslational tool in safety drug screening and basic research. How-
ver, it has to be considered that the observed responses can partly
e induced by activation of other transmission systems. The ﬁve
dentiﬁed common responses belong to the frequently reported
igns and should be at least examined when studying the SS in
MRI mice. However, we recommend to broaden the spectrum of
esponses, when other mouse strains are investigated.
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